Guggenheim lowered the firm’s price target on Universal Health (UHS) to $211 from $238 and keeps a Buy rating on the shares. The story for the quarter “ultimately boiled down to difficult optics surrounding core growth,” but UHS management reassured that an acceleration in growth moving through 2026 was “always part of the plan,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health price target lowered to $204 from $241 at Baird
- Universal Health downgraded to Market Perform from Outperform at Raymond James
- Universal Health Services Earnings Call Highlights Growth
- Universal Health Maintained at Hold as Q1 Beat Driven by Pricing Strength but Volume Trends Remain Soft
- Analyst Reiterates Sell on Universal Health as Policy Risks Offset Q1 Beat; Price Target Maintained at $215